Early and Multimodal Care for Patients with Lung Cancer: Findings from the ACCEPT Study.
6 affiliations
- 1Lung Cancer Center, Hospital Gemeinschaftskrankenhaus Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany.
- 2Research Institute Havelhöhe, Hospital Gemeinschaftskrankenhaus Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany.
- 3Charité Competence Center for Traditional and Integrative Medicine (CCCTIM), Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
- 4Gesellschaft für Klinische Forschung e.V., 10623 Berlin, Germany.
- 5Department of Pediatrics, Division of Oncology and Hematology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
- 6Interdisciplinary Oncology and Palliative Care Center, Hospital Gemeinschaftskrankenhaus Havelhöhe, 14089 Berlin, Germany.
Abstract
Objective: Treating lung cancer with a combination of targeted cancer therapy, supportive, and psychosocial treatments is important in modern oncology. The ACCEPT study investigated the efficacy of a 12-week early multimodal supportive care program on quality of life. Methods: ACCEPT was a single-center, non-randomized, prospective, open-label trial, with a pragmatic real-world design guided by patient choice. Patients with newly diagnosed, stage II-IV lung cancer participated in the outpatient ACCEPT program (psycho-oncology, health education, and training-based interventions alongside standard care). Longitudinal patient-reported outcome measures (PROMs) were collected. The primary outcome was the change in quality of life at 12 weeks measured by the Trial Outcome Index (TOI). Secondary outcomes included further exploratory PROM changes and overall survival. Results: Between April 2018 and August 2021, 214 lung cancer patients (median age 67, 53% male, 57% stage IV) were enrolled, with 116 patients evaluable for longitudinal PROM changes at 12 weeks. Participation in the multimodal ACCEPT program was associated with up to 17% improvement in the TOI, psychological distress, and sleep quality (p < 0.0001). Multivariate analyses revealed that greater session attendance was significantly and dose-dependently associated with improvements in the TOI as well as reductions in depression and anxiety. Higher engagement in multimodal sessions was also linked to reduced fatigue. Furthermore, exploratory signals of improved overall survival were observed among the 40 patients (18.7%) who fully completed the ACCEPT program. Conclusions: This pragmatic, patient-centered, multimodal supportive care program for lung cancer patients was associated with dose-dependent improvements in quality of life and psychological distress. While exploratory signals of improved survival were observed, multicenter randomized controlled trials are required to confirm these findings and firmly establish the role of such supportive care programs in routine oncology.
Related
- Multimodal digital assessment of early recovery after chest tube omission in early-stage lung cancer patients undergoing wedge resection: a post hoc analysis of a prospective cohort
- Multimodal lifestyle intervention during neoadjuvant chemotherapy in patients with early breast cancer as a strategy to improve treatment response: Protocol of the DIANA randomized clinical trial
- Epigenetic Exposure Signatures Distinguish Early-Onset from Later-Onset Colorectal Cancer in a Racially Diverse US Cohort: Findings from the Disparities and Cancer Epidemiology (DANCE) Study
- Current Role of Endoscopic Ultrasonography in the Early Detection of Pancreatic Cancer: Recognition of Indirect Imaging Findings and Diagnostic Strategy
- Autonomic nervous system dysfunction in critically ill cancer patients: Hemodynamic consequences and multimodal assessment strategies☆
BibTeX
@article{grah2026early,
title = {{Early and Multimodal Care for Patients with Lung Cancer: Findings from the ACCEPT Study.}},
author = {Christian Grah and Shiao Li Oei and Felix Kindler and Alexander Krabbe and Hannah Wüstefeld and Marcus Reif and Anja Thronicke and Steven Ngandeu Schepanski and Georg Seifert and Friedemann Schad},
journal = {Cancers},
year = {2026},
month = sep,
doi = {10.3390/cancers18193081},
url = {https://europepmc.org/article/MED/42882776},
note = {CC BY},
}
RIS
TY - JOUR
TI - Early and Multimodal Care for Patients with Lung Cancer: Findings from the ACCEPT Study.
AU - Christian Grah
AU - Shiao Li Oei
AU - Felix Kindler
AU - Alexander Krabbe
AU - Hannah Wüstefeld
AU - Marcus Reif
AU - Anja Thronicke
AU - Steven Ngandeu Schepanski
AU - Georg Seifert
AU - Friedemann Schad
PY - 2026
DA - 2026/09/22
JO - Cancers
DO - 10.3390/cancers18193081
UR - https://europepmc.org/article/MED/42882776
AB - Objective: Treating lung cancer with a combination of targeted cancer therapy, supportive, and psychosocial treatments is important in modern oncology. The ACCEPT study investigated the efficacy of a 12-week early multimodal supportive care program on quality of life. Methods: ACCEPT was a single-center, non-randomized, prospective, open-label trial, with a pragmatic real-world design guided by patient choice. Patients with newly diagnosed, stage II-IV lung cancer participated in the outpatient ACCEPT program (psycho-oncology, health education, and training-based interventions alongside standard care). Longitudinal patient-reported outcome measures (PROMs) were collected. The primary outcome was the change in quality of life at 12 weeks measured by the Trial Outcome Index (TOI). Secondary outcomes included further exploratory PROM changes and overall survival. Results: Between April 2018 and August 2021, 214 lung cancer patients (median age 67, 53% male, 57% stage IV) were enrolled, with 116 patients evaluable for longitudinal PROM changes at 12 weeks. Participation in the multimodal ACCEPT program was associated with up to 17% improvement in the TOI, psychological distress, and sleep quality (p < 0.0001). Multivariate analyses revealed that greater session attendance was significantly and dose-dependently associated with improvements in the TOI as well as reductions in depression and anxiety. Higher engagement in multimodal sessions was also linked to reduced fatigue. Furthermore, exploratory signals of improved overall survival were observed among the 40 patients (18.7%) who fully completed the ACCEPT program. Conclusions: This pragmatic, patient-centered, multimodal supportive care program for lung cancer patients was associated with dose-dependent improvements in quality of life and psychological distress. While exploratory signals of improved survival were observed, multicenter randomized controlled trials are required to confirm these findings and firmly establish the role of such supportive care programs in routine oncology.
SN - 2072-6694
ER -